MX379357B - Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica. - Google Patents

Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.

Info

Publication number
MX379357B
MX379357B MX2016006091A MX2016006091A MX379357B MX 379357 B MX379357 B MX 379357B MX 2016006091 A MX2016006091 A MX 2016006091A MX 2016006091 A MX2016006091 A MX 2016006091A MX 379357 B MX379357 B MX 379357B
Authority
MX
Mexico
Prior art keywords
ulcer
wound
application
formulation
treatment
Prior art date
Application number
MX2016006091A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006091A (es
Inventor
Alvar Grönberg
Christine Dieterich
Margit Mahlapuu
Original Assignee
Pergasus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pergasus Ab filed Critical Pergasus Ab
Publication of MX2016006091A publication Critical patent/MX2016006091A/es
Publication of MX379357B publication Critical patent/MX379357B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
MX2016006091A 2013-11-19 2014-11-19 Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica. MX379357B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
MX2016006091A MX2016006091A (es) 2016-12-09
MX379357B true MX379357B (es) 2025-03-11

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006091A MX379357B (es) 2013-11-19 2014-11-19 Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.

Country Status (15)

Country Link
US (3) US10226508B2 (enExample)
EP (1) EP3071216B1 (enExample)
JP (1) JP6539268B2 (enExample)
KR (1) KR102360938B1 (enExample)
CN (1) CN105939726A (enExample)
AU (1) AU2014351607B2 (enExample)
BR (1) BR112016011166A8 (enExample)
CA (1) CA2927557C (enExample)
ES (1) ES2925876T3 (enExample)
MX (1) MX379357B (enExample)
PL (1) PL3071216T3 (enExample)
RU (1) RU2707254C1 (enExample)
TW (1) TWI698251B (enExample)
WO (2) WO2015075406A1 (enExample)
ZA (1) ZA201604110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
US10207031B2 (en) 2010-12-08 2019-02-19 Convatec Technologies Inc. Integrated system for assessing wound exudates
ES2940916T3 (es) 2010-12-08 2023-05-12 Convatec Technologies Inc Sistema para eliminar exudados del sitio de una herida
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN105008611A (zh) 2012-12-20 2015-10-28 康沃特克科技公司 化学改性的纤维素纤维的处理
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
EP3288600B1 (en) 2015-04-28 2023-09-06 ConvaTec Technologies Inc. Antibacterial nanofibres
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
EP3436820A2 (en) 2016-03-30 2019-02-06 Qualizyme Diagnostics GmbH&Co KG Detecting microbial infection in wounds
EP3936095B1 (en) 2016-03-30 2024-06-19 ConvaTec Technologies Inc. Detecting microbial infections in wounds
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
CA3030153C (en) 2016-07-08 2023-10-24 Convatec Technologies Inc. Fluid flow sensing
BR112019000284A2 (pt) 2016-07-08 2019-04-16 Convatec Technologies Inc. aparelho de coleta de fluido
WO2018009880A1 (en) 2016-07-08 2018-01-11 Convatec Technologies Inc. Flexible negative pressure system
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
PT3638251T (pt) 2017-06-12 2024-05-22 Lakewood Amedex Inc Formulações de gel de bifosfocina e suas utilizações
CN111836655A (zh) 2017-11-16 2020-10-27 康沃特克有限公司 流体收集设备
US11123357B2 (en) 2018-10-17 2021-09-21 Lakewood Amedex, Inc. Methods and compositions for treating oral mucositis
JP7511585B2 (ja) 2019-06-03 2024-07-05 コンバテック リミティド 病原体を破壊して封じ込めるための方法およびデバイス
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JP4048565B2 (ja) 1996-04-23 2008-02-20 東レ株式会社 「抗ピロリ菌剤」
US6201164B1 (en) * 1996-07-11 2001-03-13 Coloplast A/S Hydrocolloid wound gel
US6861067B2 (en) 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
US20080226724A1 (en) * 2007-01-19 2008-09-18 Genentech, Inc. Prevention of hydrogel viscosity loss
US20100178320A1 (en) * 2007-06-25 2010-07-15 Lipopeptide Ab New medical products
US8529897B2 (en) * 2007-08-16 2013-09-10 Carnegie Mellon University Inflammation-regulating compositions and methods
BRPI0821814A2 (pt) * 2007-12-28 2015-06-16 Heraeus Kulzer Gmbh Uso e formulação tópica de eritropoietina para a cicatrização da pele
AU2010316006B2 (en) 2009-11-03 2013-09-26 Lipidor Ab Composition for promoting wound healing
CA2810844C (en) * 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
US20190255147A1 (en) 2019-08-22
ZA201604110B (en) 2020-11-25
MX2016006091A (es) 2016-12-09
WO2015075406A1 (en) 2015-05-28
AU2014351607A1 (en) 2016-06-23
US10226508B2 (en) 2019-03-12
JP2016537373A (ja) 2016-12-01
BR112016011166A2 (enExample) 2017-08-08
TWI698251B (zh) 2020-07-11
KR20160088914A (ko) 2016-07-26
AU2014351607B2 (en) 2020-03-05
US20200384077A1 (en) 2020-12-10
BR112016011166A8 (pt) 2022-06-28
US10709760B2 (en) 2020-07-14
EP3071216A1 (en) 2016-09-28
ES2925876T3 (es) 2022-10-20
RU2016124234A (ru) 2017-12-25
CN105939726A (zh) 2016-09-14
WO2015075441A1 (en) 2015-05-28
CA2927557A1 (en) 2015-05-28
RU2707254C1 (ru) 2019-11-25
JP6539268B2 (ja) 2019-07-03
TW201521760A (zh) 2015-06-16
PL3071216T3 (pl) 2022-11-21
EP3071216B1 (en) 2022-08-03
US11191810B2 (en) 2021-12-07
KR102360938B1 (ko) 2022-02-09
US20160271217A1 (en) 2016-09-22
CA2927557C (en) 2023-05-02

Similar Documents

Publication Publication Date Title
MX379357B (es) Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.
MX382195B (es) Sistema terapeutico transdermico que contiene asenapina
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
MX2016015705A (es) Dispositivo para el suministro de una composicion para el cuidado de la piel.
SA519400913B1 (ar) تركيبة موضعية لتعزيز إلتئام الجروح
NZ751231A (en) Silk-derived protein for treating inflammation
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
MY179605A (en) Use of benzimidazole-proline derivatives
MX376183B (es) Composiciones para el tratamiento de rosacea.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
MX375916B (es) Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
MX374354B (es) Método de curación de heridas.
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX350080B (es) Composicion anti-inflamatoria para coadyuvar y favorecer el proceso de cicatrizacion de lesiones ulcerosas cronicas.
WO2015057964A3 (en) Modulation of mrtf-a activity in pathologic fibrosis and wound healing
WO2015069656A8 (en) Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
UA79462U (ru) Способ местного лечения венозных трофических язв
EA201592013A1 (ru) Новые композиции для лечения хронических язв
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
MX2012002783A (es) Composicion farmaceutica que comprende un extracto hexano-acetato de etilo de ageratina pichinchensis y su uso para el tratamiento y cura de ulceras venosas cronicas.